Q2 2025 Crinetics Pharmaceuticals Inc Earnings Call Transcript

Aug 7, 2025 / 08:30 PM GMT

Release Date Price: €24.2 (+0.83%)

Transcript 10-Q8-K

Key Points

Positve

Crinetics Pharmaceuticals Inc (CRNX) is on track for the anticipated FDA approval of Paltusine in September, which could be a transformational launch for the company.
The company has assembled a strong launch team with deep expertise in endocrinology and rare disease commercialization, indicating readiness for market entry.
Crinetics Pharmaceuticals Inc (CRNX) has made significant progress in its pipeline, with multiple pivotal programs and trials ramping up, including those for carcinoid syndrome and congenital adrenal hyperplasia.
The company has a robust financial position with $1.2 billion in cash equivalents and investments, providing a runway to fund operations into 2029.
Crinetics Pharmaceuticals Inc (CRNX) has engaged extensively with healthcare professionals and patient communities, enhancing its commercial strategy and market understanding.

Negative

The company reported a significant increase in research and development expenses, rising to $80.3 million in the second quarter, reflecting high costs associated with clinical programs.
Selling, general, and administrative expenses also increased to $49.8 million, indicating substantial investment in commercial capabilities that may impact short-term profitability.
There is uncertainty regarding the timeline for the IND submissions for TSH and SST3 antagonists, with no specific granularity provided beyond targeting the end of the year.
The anticipated launch of Paltusine may face challenges due to the infrequent visits of acromegaly patients to endocrinologists, potentially leading to a slower uptake.
The company has not provided specific guidance on pricing for Paltusine, which could impact market acceptance and payer negotiations.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

CRNX.OQ - Crinetics Pharmaceuticals Inc
Q2 2025 Crinetics Pharmaceuticals Inc Earnings Call
Aug 07, 2025 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Welcome to kinetics Pharmaceuticals 2nd quarter 2025 financial results conference call. At this time, all participants run listen-only mode. Following the management's prepared remarks, we will hold a question and answer session. In order to raise a question. Please signal pressing star followed by 1 on your telephone keypad to remove yourself from the line of questioning will be followed by 2. I I would like to turn the call over to Guy 3 the Walker. Head of investor relations, please go ahead. Thank.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
You, operator.

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.